Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
ICS-M5259 | Mouse | Mouse ICOS / CD278 (C137S, C138S) Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
ICS-M52H8 | Mouse | Mouse ICOS / CD278 (C137S, C138S) Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
ICS-H5258 | Human | Human ICOS / CD278 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
ICS-H82E5 | Human | Biotinylated Human ICOS / CD278 (C136S, C137S) Protein, His,Avitag™ (recommended for biopanning) | ![]() |
![]() ![]() |
![]() ![]() |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Vopratelimab | JTX-2011 | Phase 2 Clinical | Jounce Therapeutics | Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung | Details |
Alomfilimab | KY-1044 | Phase 2 Clinical | Kymab | Liver Neoplasms; Head and Neck Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Hepatocellular | Details |
Izuralimab | XmAb-104; XmAb-23104 | Phase 1 Clinical | Xencor | Nasopharyngeal Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Breast Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms | Details |
Acazicolcept | ALPN-101 | Phase 2 Clinical | Alpine Immune Sciences, Abbvie Inc | Graft vs Host Disease; Autoimmune Diseases; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders; Inflammation | Details |
Anti-ICOS (Bristol Myers Squibb) | BMS-986226 | Phase 1 Clinical | Bristol-Myers Squibb Company | Neoplasms | Details |
Feladilimab | GSK-609; GSK-3359609 | Phase 3 Clinical | Glaxosmithkline Plc | Head and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Multiple Myeloma | Details |
This web search service is supported by Google Inc.